The importance of white adipose tissue in the control of energy balance is now firmly recognized. In addition to fuel storage, adipocytes secrete an array of proteins factors (adipokines), which regulate multiple physiological and metabolic processes as well as influence body fat accumulation. Zinc-a2-glycoprotein (ZAG), a lipid mobilizing factor initially characterized as a tumor product associated with cachexia, has recently been identified as a novel adipokine. Although the exact role of ZAG in adipose tissue remains to be clarified, there is evidence that ZAG expression appears to be inversely related to adiposity, being upregulated in cachexia whereas reduced in obesity. Investigations on the regulation of ZAG give insights into its potential function in adipose tissue with a link to lipid mobilization and an anti-inflammatory action. Recent work shows that ZAG stimulates adiponectin secretion by human adipocytes. Data from genetic studies suggest that ZAG may be a candidate gene for body weight regulation; this is supported by the demonstration that ZAG-knockout mice are susceptible to weight gain, whereas transgenic mice overexpressing ZAG exhibit weight loss. The present review summarizes these new perspectives of ZAG and the potential mechanisms by which it might modulate adipose tissue mass and function.
Introduction
White adipose tissue has an important metabolic function by storing triacylglycerol in periods when energy input exceeds expenditure and releasing free fatty acids during energy deprivation. 1 Over the last decade, white fat has also become recognized as a major endocrine organ, as the tissue synthesizes and secretes an array of protein hormones and signals, named adipokines. [2] [3] [4] [5] [6] [7] These adipokines, which include leptin, adiponectin, tumor necrosis factor-a (TNFa), interleukin (IL)-6, visfatin and the recently described chemerin, act locally in an autocrine/paracrine manner and/or as endocrine signals to regulate appetite, energy expenditure and a range of other physiological processes such as insulin sensitivity, inflammation, angiogenesis and extracellular matrix remodeling. [8] [9] [10] In addition, as the largest energy reserve in the body, adipose tissue has a major impact on energy flux, plasma lipid levels and glucose uptake. A large body of evidence indicates that alterations in adipose tissue mass and metabolism have profound effects on whole body energy homeostasis. 11 It has been shown that too much body fat (obesity), or too little (lipodystrophy), are major risks for insulin resistance, dyslipidaemia, type-2 diabetes and cardiovascular disease. 12 With the escalation in obesity and its associated metabolic disorders, understanding the factors and intrinsic mechanisms that regulate adipose tissue accumulation becomes increasingly important. Evidence has emerged that some of the adipokines, particularly leptin and adiponectin, have crucial roles in the control of adiposity and therefore in overall metabolic health. Zinc-a2-glycoprotien (ZAG, also known as AZGP1), with a close link to lipid metabolism, has been identified as a novel adipokine by our recent work. 13, 14 Here, we present an overview of ZAG and new perspectives on its potential role in adipose tissue plasticity and function.
ZAG structure and function ZAG, a soluble protein of approximately 41 kDa, was first isolated from human plasma. 15 Subsequently, ZAG was identified in secretory epithelial cells, including those of liver, breast, prostate, the gastrointestinal tract and sweat glands. 16 ZAG is overexpressed by several types of malignant tumors, such as cancers of breast, prostate, bladder and lung. [17] [18] [19] [20] As serum ZAG levels are elevated in patients with prostate 18,21 and cervical 22 cancers, ZAG has been proposed to serve as a potential biomarker for these carcinomas. The crystal structure of ZAG purified from human serum reveals a high degree of similarity between ZAG and class I major histocompatibility complex molecules. 23 Although the biological functions of ZAG remain to be identified, the protein has been implicated in certain cellular processes. Overexpression of ZAG in SiHa tumor cells hinders cell proliferation and reduces gene expression of cdc2, a cyclin-dependent kinase linked to increased proliferation and decreased differentiation of advanced tumors. 27 Agedependent loss of proliferative capacity of renal epithelial cells has been reported to be accompanied by a significant increase in ZAG mRNA and protein expression. 28 Treatment with recombinant ZAG suppresses renal epithelial cell proliferation, whereas ZAG knockdown with small interference RNA increases proliferation. 28 In addition, ZAG inhibits melanin production by normal and malignant melanocytes. 29 ZAG was also detected in human seminal plasma at high concentrations, 30 and has been shown to be involved in sperm motility. 31 However, the most studied property of ZAG is its involvement in lipid metabolism associated with adipose tissue atrophy in cachexia.
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ZAG: a lipid-mobilizing factor
The lipolytic action of ZAG was not recognized until a lipidmobilizing factor, purified from the urine of patients with cancer cachexia and from a murine cachexia-inducing tumor (MAC16), was shown to be identical to ZAG in electrophoretic mobility, immunoreactivity and amino-acid sequence. 33 Treatment with purified ZAG can cause selective reduction in body fat, without affecting body water, non-fat mass and food intake, in both genetically obese (ob/ob) mice and outbred NMRI mice. 34 It was also reported that mice implanted with a human ZAG gene-overexpressed tumor (xenograft) exhibit a rapid decrease in body weight. 29 In vitro, ZAG has been shown to stimulate lipolysis in isolated mouse epididymal adipocytes in a dose-dependent manner. 34 The lipolytic effect of ZAG has been postulated to be mediated by the b3-adrenoceptor through the activation of the cyclic AMP pathway. 34 This is supported by the studies in which ZAG produced comparable increases in intracellular cyclic AMP levels to that obtained with isoprenaline, and ZAG-induced lipolysis can be attenuated by the specific b3-adenoceptor antagonist (SR59230) in adipocytes. [34] [35] [36] In addition to lipid mobilization, there is also evidence that ZAG promotes lipid utilization. In vivo studies have shown that ZAG stimulates overall fatty acid oxidation in NMRI mice and ob/ob mice. 36, 37 Furthermore, administration of ZAG leads to an upregulation of mitochondrial uncoupling protein (UCP)-1 mRNA and protein expression in brown adipose tissue, 37,38 a tissue recognized for its key role in energy expenditure through thermogenesis. 39 In vitro, ZAG induces expression of UCP-1 protein 40 and oxygen uptake 34 in primary cultures of brown adipocytes. Treatment with ZAG has also been shown to increase UCP-2 and -3 mRNA levels in skeletal muscle in mice, 37, 38 and UCP-2 and -3 protein expression in murine myotubes. 40 Hence, by upregulating UCPs in brown adipose tissue and muscle, ZAG may provide a mechanism for the utilization of excess fatty acids liberated from enhanced lipolysis.
Identification of ZAG as a new adipokine
Adipose tissue as an important endocrine organ not only stores triglyceride as a fuel reserve, but also regulates energy homeostasis and other physiological processes. 1, 4 Adipose tissue has extensive crosstalk with the brain, liver and skeletal muscle through its secreted adipokines. Over the past decade, a growing number of adipokines have been identified, as noted earlier, and nearly 100 such secreted protein factors have now been identified, which interact with a multiplicity of physiological and metabolic processes. The secretory function of adipose tissue and the powerful fatlowering effects of ZAG led to the postulate that this protein could also be produced by adipose tissue and might act as a novel factor in adipocyte metabolism. 13 Our work has demonstrated that the ZAG gene is expressed and the protein is present in the major white fat depots (epididymal, perirenal, subcutaneous, mammary gland) and in the interscapular brown fat of mice. 13 Using immunocytochemistry, ZAG protein was detected in the cytoplasm of adipocytes in adipose tissue. 13 Following collagenase digestion of white fat, the ZAG transcript was found to be present in both the stromal vascular cells and in mature adipocytes. ZAG is also detectable in cultured murine 3T3-L1 adipocytes. 13 In human subjects, ZAG mRNA and protein are evident in adipose tissue, both visceral and subcutaneous. 13 Further studies using paired visceral and subcutaneous samples do not show depot differences at either the mRNA or protein levels. 41 ZAG gene expression and ZAG protein have both been detected in isolated human fat cells, SGBS ZAG and adiposity C Bing et al (Simpson-Golabi-Behmel syndrome) human adipocyte cell strain 14 and human primary adipocytes (ZenBio). 42 Importantly, ZAG, which contains a secretory signal sequence, 18 is secreted into the culture medium by differentiated adipocytes. 14 Also importantly, the level of ZAG release by human adipocytes has recently been demonstrated to be comparable with that of adiponectin (which is one of the most abundant proteins in adipose tissue). 41 Collectively, these findings indicate that ZAG is a major adipokine produced abundantly by human adipocytes. From this it seems probable that adipocyte-derived ZAG may have an autocrine/paracrine action locally, and will also contribute to circulating levels of the protein, in the control of adipose tissue mass and function ( Figure 1 ).
Regulation of ZAG expression in adipose tissue and adipocytes
Although the full regulation of ZAG production in adipose tissue has not been established, several factors including hormones and other agents have been shown to modulate ZAG gene expression in adipocytes. Glucocorticoids appear to stimulate ZAG expression as dexamethasone increases ZAG mRNA in both 3T3-L1 and SGBS adipocytes. 13, 14 This is supported by a study in which the stimulatory effect of dexamethasone on ZAG protein expression in 3T3-L1 adipocytes was abolished by the glucocorticoid receptor antagonist (RU38486). 43 It has been shown that dexamethasone reduces visceral fat mass and enhances catecholaminestimulated lipolysis in rats, 44 and cortisol infusion increases adipose tissue and systemic lipolysis in humans. 45 As cachexia is associated with elevated serum cortisol in mice bearing the MAC-16 tumor 43 and in cancer patients, 46 the lipolytic effects of glucocorticoids may act at least in part through upregulation of ZAG expression in adipocytes. Treatment with eicosapentaenoic acid, which prevented weight loss in tumor-bearing mice, led to a downregulation of ZAG protein expression in adipose tissue and attenuated dexamethasone-induced increase in ZAG in 3T3-L1 adipocytes. 47 BRL 37344, a selective b3-adrenoceptor agonist, has also been shown to increase ZAG mRNA levels in 3T3-L1 and SGBS cells. 13, 14 In contrast, SR59230A, the specific b3-adrenoceptor antagonist, inhibits ZAG protein expression in 3T3-L1 cells. 36 It is therefore probable that the sympathetic system is involved in the regulation of ZAG expression, and it may operate through b3-adrenoceptors, which are the major receptor subtype in stimulating lipolysis in rodent adipose tissue. However, whether the lipolytic effects of ZAG may also be mediated through b1-or b2-adrenoceptors are not known and this is important in relation to the role of ZAG in human adipose tissue, in which b3-adrenoceptors appear to be of limited significance. Intriguingly, ZAG expression in 3T3-L1 adipocytes is also upregulated by the treatment with purified ZAG, and this can be attenuated by SR59230A. 36 Treatment with rosiglitazone, an insulin-sensitizing agent, elicits a rise in ZAG mRNA, similar to its effect on adiponectin, implying that the PPARg nuclear receptor is involved in the regulation of ZAG synthesis. In contrast, the pleiotrophic proinflammatory cytokine TNFa induces a dose-dependent decrease in ZAG mRNA levels, and this again parallels the changes that occur in adiponectin gene expression.
14 As the stimulatory effect of rosiglitazone and the inhibitory effect of TNFa on ZAG synthesis mirror the regulation of adiponectin by these two factors, there may be a potential link between the two adipokines. Taken together, studies in vitro indicate that ZAG expression is regulated by certain hormones and drugs that influence lipolysis and inflammatory response. Whether ZAG could be involved in mitigating inflammation in adipose tissue in vivo awaits further studies.
ZAG expression and body fat mass
As a novel adipokine, a key question is whether ZAG has a role in the control of fat mass. Growing evidence suggests that ZAG expression in adipose tissue is inversely associated with body fat mass. In mice bearing the MAC16 tumor, which induces a profound loss of body fat, ZAG mRNA and protein levels were substantially increased (both by 10-fold) in adipose tissue; furthermore, the increase in ZAG protein content is related to the amount of weight loss. 13 In contrast, leptin mRNA in adipose tissue and circulating leptin levels were markedly decreased in cachectic mice. 13, 48 In addition to cachexia, feeding a low-calorie diet has very recently been found in microarray studies to lead to a modest increase ZAG and adiposity C Bing et al in ZAG mRNA level in subcutaneous adipose tissue of obese women. 49 ZAG is also implicated in the development of adipose tissue by our recent study in rats during the first month after birth, in which ZAG protein levels were reduced at weaning when there is a large increase in fat mass. 50 A downregulation of ZAG expression in obesity has recently been reported in mice as well as in humans. ZAG mRNA and protein expression in adipose tissue (both epididymal and subcutaneous) and the liver are reduced in obese ob/ob mice. 51 In obese Zucker rats, ZAG mRNA levels in epididymal and retroperirenal adipose tissue are decreased too. 51 Similar to the findings in genetic models of obesity, a decrease in adipose tissue ZAG mRNA and serum ZAG levels has been reported in mice, in which obesity is induced by a high-fat diet. 52 In human subjects, using a gene profiling approach ZAG transcripts have been reported to be decreased in subcutaneous fat of obese women. 53 ZAG gene and protein expression has also been shown to be downregulated in subcutaneous and visceral adipose tissue of obese men and women in comparison with lean controls. [54] [55] [56] Interestingly, a negative correlation between adipose-derived ZAG and body mass index or total body fat mass in human subjects has been demonstrated by studies from our group and from others. 41, 55, 56 Reduced ZAG expression in adipose tissue in the obese state may therefore be linked to impaired adipose tissue metabolism in obesity. In addition, there is an inverse association between ZAG and parameters of insulin resistance; ZAG mRNA in both visceral and subcutaneous depots is negatively correlated with plasma insulin levels or the homeostasis model of insulin resistance. 41, 56 An inverse relationship has also been found between ZAG mRNA and plasma C-reactive protein or monocyte chemotactic protein-1, both of which are important in inflammatory responses and predict an increased risk of type 2 diabetes. 41 Moreover, ZAG mRNA levels in subcutaneous depot were downregulated in patients with the metabolic syndrome compared with those without. 56 Thus, decreased ZAG expression with increased insulin resistance may indicate a protective role of ZAG in maintaining appropriate fat mass and insulin sensitivity. However, the data on serum ZAG levels in relation to obesity are inconsistent, being reported as decreased, 52, 55 unchanged 57 or increased. 58 Circulating ZAG levels have been shown to be negatively 56 or positively 58 correlated with insulin and the insulin resistance indices. It is possible that adipose tissue-derived ZAG is more important locally through its autocrine/paracrine actions.
ZAG: a candidate gene for obesity
Studies in KK/Ta mice, a spontaneous animal model of type 2 diabetes, have suggested that ZAG is a possible candidate gene for obesity. 59 A single-nucleotide polymorphism in exon 2 of the ZAG gene was identified in KK/Ta mice and this polymorphism, a missense mutation at codon 24, may contribute to a type 2 diabetes-related phenotype involving obesity. 59 Further genetic evidence was provided by the demonstration that ZAG-knockout mice were susceptible to weight gain, particularly after a high-fat diet. 60 This phenotype appears to be the result of reduced lipolytic responses to several stimuli, including isoprenaline, CL316243 (a b3-agonist), foskolin and isobutylmethylxanthine, in adipocytes. 60 In contrast, ZAG-overexpressing transgenic mice exhibited decreased body weight and epididymal fat, which was accompanied by a reduction in mRNA levels of fatty acid synthase, acetyl-CoA carboxylase-1 and acyl-coenzyme A: diacylglycerol transferase and the increase in mRNA levels of hormone-sensitive lipase in epididymal adipose tissue. 52 The potential role of ZAG in cholesterol metabolism has also been implicated by a recent study, in which a polymorphism in the ZAG gene is found to be associated with total cholesterol and low-density lipoprotein cholesterol in human subjects. 61 In addition to lipid metabolism, ZAG may be involved in the regulation of adiposity through modulating the production of other adipokines. Recent studies by our group and others reveal a positive association between ZAG mRNA and adiponectin mRNA levels in both visceral and subcutaneous fat of human subjects. 41, 56 Adiponectin, primarily expressed in adipocytes, is considered to have insulin-sensitizing as well as anti-inflammatory properties. 62 Contrary to other adipokines, such as leptin, TNFa and monocyte chemotactic protein-1, whose levels increase with fat mass accumulation, 63, 64 circulating adiponectin decreases in obesity. 65 There is evidence that adiponectin acts through activation of AMP kinase to stimulate glucose uptake and fatty acid oxidation in skeletal muscle, and decreases vascular inflammation. 66 The parallel expression pattern for the two adipokines together with the similar regulation by rosiglitazone and TNFa 14 may suggest that ZAG could act similarly to adiponectin in protecting against the obese state. A potential functional link between ZAG and adiponectin was initially postulated from a study in which overexpression of ZAG in 3T3-L1 adipocytes was found to lead to a rise in adiponectin transcripts. 59 Our recent study has further examined whether ZAG modulates adiponectin production in human SGBS adipocytes. We have demonstrated that recombinant ZAG, at physiologically relevant concentrations, increases adiponectin release from differentiated human adipocytes. 41 This finding suggests that ZAG may act in a paracrine manner to stimulate adiponectin secretion by adipocytes, and therefore could be important in promoting the insulin-sensitizing and anti-inflammatory (and other) actions of adiponectin. Leptin, another key adipokine, is involved in the control of body adiposity by its central and peripheral actions. 67, 68 It is well documented that leptin expression in adipose tissue and circulating leptin are elevated in obese subjects. 69 A negative correlation between ZAG and leptin mRNA levels has been found in both visceral and subcutaneous fat in human subjects. 41 It is also reported that ZAG mRNA levels ZAG and adiposity C Bing et al in subcutaneous fat negatively correlate with plasma leptin levels in obese men. 54 Recently, we have demonstrated an inhibitory effect of ZAG on leptin production in vitro, as the treatment with recombinant ZAG led to a decrease in leptin release by differentiated SGBS cells. 70 Taken together, these results suggest that ZAG may have at least a partial role in regulating the production of adipokines involved in satiety and energy balance in adipose tissue. Thus, ZAG may indeed be implicated in the susceptibility to obesity.
Conclusion
The identification of ZAG as an adipokine raises questions as to its potential regulatory functions in adiposity and metabolism. Although the exact mode of ZAG action in adipose tissue remains to be established, ZAG expression appears to be inversely linked to body fat mass, being upregulated in cachexia, whereas reduced in obesity. Data from genetic studies suggest that ZAG may serve as a candidate gene for obesity. Further studies using loss or gain of function of ZAG in vivo provide evidence for a role for this adipokine in the stimulation of lipolysis and the inhibition of lipid accumulation in adipose tissue. In addition, recent studies demonstrate that the involvement of ZAG in adiposity and metabolism could be through its effect on the production of adiponectin; ZAG overexpression in 3T3-L1 adipocytes increases adiponectin mRNA and recombinant ZAG enhances adiponectin release by human adipocytes (Figure 2 ). Taken together, it is suggested that ZAG may have a protective role, through its lipid-mobilizing effect or by indirect actions such as stimulating adiponectin production, in the prevention of obesity and its associated disorders. Although the notion that as an adipokine ZAG may have a major autocrine/paracrine role in adipose tissue is persuasive, more in vivo and in vitro studies are required to further unravel its function, regulation and possible clinical significance in the modulation of adiposity. The potential importance of ZAG in adipose tissue function is underscored by its abundant production by adipocytes. ZAG and adiposity C Bing et al
